The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

IRIS Biotechnologies Issued a Notice of Allowance of Its Key Patent Application Artificial Intelligence System for Genetic Analysis

14-Jun-2016 | Source : Iris Biotechnologies | Visits : 6872
SANTA CLARA, Calif. - Iris Biotechnologies announced in a press release that the Japanese Patent Office has issued a notice of allowance of its Artificial Intelligence System for Genetic Analysis to be granted as a patent. This follows the issuance of a family of patents in the US, EU, Canada, Hong Kong, Australia, and New Zealand.
A critical mass of scientific knowledge, instrumentation and affordable computing power is at hand, yet a critical piece has been missing which Iris is now able to provide: smart integration of genomic, proteomic, lifestyle, family history and environmental information. Iris is poised to play a leading role in answering the unmet needs of a multi-billion-dollar market.
“Compared to when Iris Biotechnologies common stock (IRSB) was trading at $4.50 per share, the Company now has more patents worldwide and is planning to launch the first Iris Wellness Labs this summer,” said Iris CEO Simon Chin. To read more about Iris Wellness services, please visit under Quick Links.
Iris Biotechnologies Inc., unlike other life sciences companies, focuses on providing accurate, affordable precision healthcare through comprehensive analysis of the whole person inside and out. Iris offers the best approach to the treatment of cancer and other diseases through incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personalized, cost-effective healthcare and is the future of precision medicine. 

Related Articles